{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:46:22Z","timestamp":1785797182736,"version":"3.56.0"},"reference-count":17,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medicine"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To identify useful biomarkers by reviewing laboratory data for a predictor of the clinical course following treatment with radium-223 dichloride (Ra-223) in patients with metastatic castration-resistant prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eighteen metastatic castration-resistant prostate cancer patients who were administered Ra-223 at our hospital were retrospectively enrolled in this study. Prostate-specific antigen doubling times before and after the administration of Ra-223 were evaluated as prognostic factors for metastatic castration-resistant prostate cancer patients treated with Ra-223 using the Kaplan\u2013Meier method and Log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Four patients failed to complete the planned six-time Ra-223 treatments with the exacerbation of their condition. In the 14 patients who completed the planned Ra-223 treatment, before the Ra-223 treatment, no significant differences were observed in overall survival between patients with prostate-specific antigen doubling time of 6\u2009months or less and those with prostate-specific antigen doubling time of more than 6\u2009months or stable ( p\u2009=\u20090.642). Following the completion of the Ra-223 treatment, overall survival was significantly shorter in patients with prostate-specific antigen doubling time of 6\u2009months or less than in those with prostate-specific antigen doubling time of more than 6\u2009months or stable ( p\u2009=\u20090.007).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Prostate-specific antigen doubling time after the Ra-223 treatment is a useful predictor of the clinical course following treatment in metastatic castration-resistant prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20503121231168493","type":"journal-article","created":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T04:37:00Z","timestamp":1682138220000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1177","volume":"11","author":[{"given":"Gen","family":"Kawaguchi","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-8364","authenticated-orcid":false,"given":"Tsutomu","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,22]]},"reference":[{"key":"bibr1-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13593"},{"key":"bibr2-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.039"},{"key":"bibr3-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"bibr4-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86033-4"},{"key":"bibr5-20503121231168493","unstructured":"Memorial Sloan-Kettering Cancer Center cancer information: prostate cancer nomogram, https:\/\/www.mskcc.org\/nomograms\/prostate\/psa_doubling_time"},{"key":"bibr6-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.23.2760"},{"key":"bibr7-20503121231168493","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S122417"},{"key":"bibr8-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90309-J"},{"key":"bibr9-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30173-5"},{"key":"bibr10-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.05.012"},{"key":"bibr11-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01776-w"},{"key":"bibr12-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2011.02.003"},{"key":"bibr13-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3459"},{"key":"bibr14-20503121231168493","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.195677"},{"key":"bibr15-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001005"},{"key":"bibr16-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.43"},{"key":"bibr17-20503121231168493","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4051-y"}],"container-title":["SAGE Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121231168493","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20503121231168493","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121231168493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:25:27Z","timestamp":1777595127000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20503121231168493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":17,"alternative-id":["10.1177\/20503121231168493"],"URL":"https:\/\/doi.org\/10.1177\/20503121231168493","relation":{},"ISSN":["2050-3121","2050-3121"],"issn-type":[{"value":"2050-3121","type":"print"},{"value":"2050-3121","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"20503121231168493"}}